---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: REVEAL part A"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: REVEAL part A. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 65 evidence topics quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence/reveal-part-a"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: REVEAL part A

<a id="heading-3.1.3"></a>

## 3.1.3 REVEAL Part A

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Objectives of the pooled REVEAL Part A analysis

> “To investigate the safety and preliminary efficacy of low- and high-dose TSHA-102 in adolescent/adult and pediatric females with Rett syndrome (RTT)”
> “Evaluate two dose levels to, if possible, establish maximum administered dose (MAD) or maximum tolerated dose (MTD)”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.1-2"></a>

#### Adolescent and adult trial (NCT05606614 Part A): registered objective

> “REVEAL Part A (Phase 1/2) is an open-label safety and dose-finding study designed to evaluate the safety and preliminary efficacy of two dose levels of TSHA-102 to establish initial safety of TSHA-102 and select a safe and efficacious dose for further evaluation.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.1-3"></a>

#### Pediatric trial (NCT06152237): registered objective

> “The REVEAL Pediatric Study is a multi-center, Phase 1/2 open-label, dose-escalation and dose-expansion study of TSHA-102, an investigational gene therapy, in pediatric females with Rett Syndrome.”
> “The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated.”

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Adolescent and adult trial (NCT05606614): registry dates

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2023-03-06” |
| Primary completion (estimated) | “2031-06” |
| Study completion (estimated) | “2031-06” |
| Last update posted | “2026-07-07” |

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.2-2"></a>

#### Adolescent and adult trial (NCT05606614): registered sites for Parts A and B

| Country | Registry record |
| --- | --- |
| United States | “City of Hope” |
| United States | “UC San Diego” |
| United States | “UC San Francisco Benioff Children's Hospital” |
| United States | “Rush University Medical Center” |
| United States | “Kennedy Krieger Institute” |
| United States | “Boston Children's Hospital” |
| United States | “Washington University, St. Louis” |
| United States | “UT Southwestern Children's Medical Center” |
| Canada | “CHU St. Justine” |

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.2-3"></a>

#### Pediatric trial (NCT06152237): registry dates

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2023-12-12” |
| Primary completion (estimated) | “2028-11-02” |
| Study completion (estimated) | “2031-11-02” |
| Last update posted | “2025-10-15” |

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.2-4"></a>

#### Pediatric trial (NCT06152237): registered sites

| Country | Registry record |
| --- | --- |
| United States | “Rush University Medical Center & Children's Hospital” |
| United States | “Gillette Children's Specialty Healthcare” |
| United States | “Washington University, St. Louis” |
| Canada | “CHU Ste-Justine” |
| United Kingdom | “Children's Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust” |

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.2-5"></a>

#### First adult participant dosed in Canada, June 2023

> “DALLAS, June 05, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that the first patient has been dosed with TSHA-102 in the Phase 1/2 REVEAL trial evaluating the safety and preliminary efficacy of TSHA-102 in adult patients with Rett syndrome.”
> “The study is being conducted at CHU Sainte-Justine, the Université de Montréal mother and child university hospital centre in Montreal, Canada.”

Source: [Taysha Gene Therapies first participant dosed announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-patient-dosed-tsha-102)

<a id="topic-3.1.3.2-6"></a>

#### First pediatric participant dosed in the United States, January 2024, and United Kingdom authorization

> “Initial dosing in the REVEAL Phase 1/2 pediatric trial took place at RUSH University Medical Center in Chicago under Principal Investigator Elizabeth Berry-Kravis, M.D., Ph.D., Professor of Pediatrics, Neurology and Anatomy/Cell Biology at RUSH University Medical Center.”
> “The Company also announced the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Clinical Trial Application (CTA) for TSHA-102 in pediatric patients, enabling expansion of the ongoing U.S. REVEAL pediatric trial into the U.K.”

Source: [Taysha Gene Therapies first pediatric participant dosed announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-pediatric-patient-dosed)

<a id="topic-3.1.3.2-7"></a>

#### Expansion of the adolescent and adult trial into the United States, February 2024

> “The Company also announced the expansion of its ongoing REVEAL Phase 1/2 adolescent and adult trial in Canada into the United States (U.S.) following submission of the adolescent and adult trial protocol to the U.S. Food and Drug Administration (FDA).”
> “The trial is taking place in Canada and the U.S.”

Source: [Taysha Gene Therapies clinical program update announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-updates-tsha-102-clinical)

<a id="topic-3.1.3.2-8"></a>

#### Completion of Part A dosing and data cutoffs

> “Dosing of the 10 patients with Rett syndrome in Part A, the dose escalation portion of the REVEAL Phase 1/2 adolescent/adult trial and the REVEAL Phase 1/2 pediatric trial, has been completed.”

Source: [Taysha Gene Therapies full-year 2024 results announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525035882/d920809dex991.htm)

> “As of May 2026 data cut, 12 patients (low dose, N=4; high dose, N=8) had received TSHA-102.”
> “Here, we present longer-term safety and efficacy data from REVEAL Part A, including all 12 patients with ≥12 months of follow-up, with data extending up to 30 months for the earliest treated patient”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Pooled design as reported with the 12-month results

> “REVEAL is an ongoing Phase 1/2, open-label, dose-escalation (Part A) and dose-expansion (Part B), registrational, multi-center trial, using each patient as their own control”
> “Safety monitoring included clinical/laboratory evaluations”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.3-2"></a>

#### Two first-in-human trials described together as Part A

> “The REVEAL Phase 1/2 Adolescent and Adult Trial, also known as Part A, is a first-in-human, open-label, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 as a single lumbar intrathecal administration in adolescent and adult females aged 12 years and older with Rett syndrome due to loss-of-function mutation in the methyl-CpG binding protein 2, or MECP2, gene.”
> “Part A also includes the REVEAL Phase 1/2 Pediatric Trial, which is a first-in-human, open-label, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 as a single lumbar intrathecal administration in pediatric females aged 5 to 8 years with Rett syndrome due to loss-of-function mutation in the MECP2 gene.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.3.3-3"></a>

#### Adolescent and adult trial (NCT05606614): registered design elements

| Design element | Registry record |
| --- | --- |
| Phase (record now covers Parts A and B) | “Phase 3” |
| Allocation | “Non-Randomized” |
| Intervention model | “Sequential Assignment” |
| Masking | “Single (Outcomes Assessor)” |
| Masking description | “Central raters assessing the gain or regain of a developmental milestone from videos are blinded to the timing of each video.” |
| Follow-up | “Each participant will be followed for the observation period of 5 years after TSHA-102 administration in Part A and B.” |

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.3-4"></a>

#### Pediatric trial (NCT06152237): registered design elements

| Design element | Registry record |
| --- | --- |
| Allocation | “Randomized” |
| Intervention model | “Sequential Assignment” |
| Masking | “None (Open Label)” |
| Study duration | “The study duration is up to 6 years.” |

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.3-5"></a>

#### Dose-escalation rules with Independent Data Monitoring Committee review (pediatric protocol design)

> “Part A is an open-label, single-arm dose-escalation study evaluating 2 doses of TSA-102 and is intended to define a maximum tolerated or maximum administered dose (MTD or MAD) (Figure 3).”
> “Finding of 1 DLT will trigger expansion of Cohort 1 to 6 participants; should two DLTs occur in Cohort 1, the initial dose will have surpassed the MTD.”
> “For outcomes with potential evaluator bias, participant videos will be assessed by independent experts blinded to participants’ treatment status.”

Source: [Devidze et al. (2023)](https://tayshagtx.com/wp-content/uploads/Design-of-the-REVEAL-Pediatric-study-of-TSHA-102-gene-therapy-for-Rett-Syndrome.pdf)

<a id="topic-3.1.3.3-6"></a>

#### Independent Data Monitoring Committee approval of dose escalation

> “The Independent Data Monitoring Committee (IDMC) approved the Company’s request to proceed to dose escalation in the REVEAL Phase 1/2 adolescent and adult trial, enabling earlier advancement to the high dose cohort of 1x1015 total vg.”

Source: [Taysha Gene Therapies clinical program update announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-updates-tsha-102-clinical)

> “Received Independent Data Monitoring Committee (IDMC) approval to continue with enrollment in cohort two (high dose, 1x1015 total vector genomes (vg)) across both REVEAL Phase 1/2 trials, following review of available clinical data from the first two adolescent/adult patients and the first pediatric patient treated with the high dose of TSHA-102”

Source: [Taysha Gene Therapies third quarter 2024 results announcement (2024)](https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/d877348dex991.htm)

<a id="topic-3.1.3.3-7"></a>

#### Part B design as planned before the pivotal trial replaced it

> “Patients will be randomized 3:3 to DTC or ITC in each Cohort in Part B”

Source: [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Key inclusion criteria common to both trials

> “Females with pathogenic confirmation of MECP2 mutation”
> “Clinical Global Impression Scale-Severity (CGI-S) score ≥4 at screening”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.4-2"></a>

#### Adolescent and adult trial (NCT05606614): registered criteria

> “Females between the ages of 12 and <22 in Part A (closed) and females between the ages of 6 and <22 in Part B (pivotal cohort).”
> “Participant has a clinical diagnosis of classic/typical Rett syndrome with a documented pathogenic mutation of the methyl-CpG-binding protein 2 (MECP2) gene that results in loss of gene function.”
> “Participants and parent/caregiver must agree to reside within easy access to the study site prior to the baseline visit and at least 3 months after TSHA-102 treatment”
> “Participant has another neurodevelopmental disorder independent of the MECP2 loss-of-function mutation, or any other genetic syndrome with a progressive course.”
> “Participant has a diagnosis of atypical Rett syndrome or a MECP2 gene mutation that does not cause Rett syndrome.”
> “Participant requires invasive ventilatory support.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.4-3"></a>

#### Adolescent and adult trial: eligibility extended from adults to age 12 and older, November 2023

> “Health Canada authorized the Company’s protocol amendment that expands eligibility to include patients aged 12 and older with stage four Rett syndrome in the REVEAL Phase 1/2 adult trial in Canada”

Source: [Taysha Gene Therapies adolescent eligibility announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-expanded-eligibility-reveal)

<a id="topic-3.1.3.4-4"></a>

#### Pediatric trial (NCT06152237): registered criteria

> “Participant has a confirmed diagnosis of classical/typical Rett Syndrome with a documented mutation of the MECP2 gene that results in loss of function.”
> “Participant is between ≥5 to ≤8 years of age at the time of consent.”
> “Participant must be up to date with all relevant local vaccination requirements, with last vaccination dose received at least 42 days prior to the start of the immunosuppression regimen.”
> “Participant requires non-invasive and invasive ventilatory support.”
> “Participant has contraindications for IT administration of TSHA-102 or lumbar puncture procedure, other medical conditions, or contraindications to any medications required for IT administration.”
> “Participant has acute or chronic hepatitis B or C infections.”

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.4-5"></a>

#### Pediatric trial: stage three disease at entry

> “Initiation of REVEAL pediatric trial in the U.S. broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old with stage three Rett syndrome”

Source: [Taysha Gene Therapies first pediatric participant dosed announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-pediatric-patient-dosed)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Registered dose levels (adolescent and adult trial)

> “TSHA-102 Dose Level 1: 5.7×10¹⁴ total vector genomes (vg). Participants receive a single intrathecal (IT) administration of TSHA-102 at Dose Level 1 (fully enrolled, 2 participants).”
> “Participants receive a single intrathecal (IT) administration of TSHA-102 at Dose Level 2 (fully enrolled, 4 participants).”
> “TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.5-2"></a>

#### Dose cohorts pooled across both trials

> “We have completed dosing of the 12 patients aged 6 to 21 years in Part A of both REVEAL trials, which includes eight patients in cohort two (high dose, 1x1015 total vector genomes, or vg) and four patients in cohort one (low dose, 5.7x1014 total vg).”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.3.5-3"></a>

#### Immunosuppression and intrathecal administration

> “Following immunosuppression initiation at Day −7, a single dose of TSHA-102 was delivered via intrathecal infusion through lumbar puncture on Day 0”

Source: [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf)

> “Immunoprophylaxis will begin at Day –7 and will be tapered from Week 17 to Week 25 (oral prednisolone) and starting from Week 38 (sirolimus).”

Source: [Devidze et al. (2023)](https://tayshagtx.com/wp-content/uploads/Design-of-the-REVEAL-Pediatric-study-of-TSHA-102-gene-therapy-for-Rett-Syndrome.pdf)

<a id="topic-3.1.3.5-4"></a>

#### Immunosuppression taper timing in the first two adult participants

> “Steroid taper completed Week 36, sirolimus taper completed Week 43”
> “Steroid taper completed Week 25, sirolimus taper completed Week 31”

Source: [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf)

<a id="topic-3.1.3.5-5"></a>

#### Low dose as stated before the first participant was dosed

> “Dose escalation will evaluate two dose levels of TSHA-102 sequentially, with an initial dose of 5x1014 total vector genomes (vg) and the second dose of 1x1015 vg.”

Source: [Taysha Gene Therapies first participant dosed announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-patient-dosed-tsha-102)

<a id="topic-3.1.3.5-6"></a>

#### Comparability of Part A clinical material with the commercial process

> “All process parameters and analytical results met predefined PPQ acceptance criteria and FDA-aligned comparability requirements, demonstrating that the final commercial process produces product comparable to the clinical material used in the REVEAL and ASPIRE trials.”
> “These results support the potential inclusion of REVEAL Part A data in the planned BLA submission, and we believe that the 6- and ≥12-month Part A results further support the potential for BLA submission based on the pivotal trial interim analysis.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Registered primary outcome: adolescent and adult trial

> “Part A: Safety and Tolerability of TSHA-102”
> “Proportions of participants experiencing any treatment-emergent adverse events (AEs) and serious adverse events (SAEs)”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-3.1.3.6.1-2"></a>

##### Registered primary and exploratory outcomes: pediatric trial

> “The incidence of participants experiencing any treatment-emergent adverse events (AEs) and serious adverse events (SAEs)”
> “Change from baseline in participant's status after TSHA-102 administration as assessed by Clinical Global Impressions Improvement (CGI-I).”
> “Change from baseline in participant's status after TSHA-102 administration as assessed by Revised Motor Behavior Assessment (R-MBA).”
> “Change from baseline in participant's status after TSHA-102 administration as assessed by Rett Syndrome Behavior Questionnaire (RSBQ).”
> “The percent change from the steroid-free baseline period in monthly countable seizure frequency (MCSF).”

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.6.1-3"></a>

##### Safety as the first objective of a first-in-human dose escalation

> “The REVEAL adolescent/adult (NCT05606614) and pediatric (NCT06152237) studies are first-in-human trials of TSHA-102 for individuals with Rett syndrome”
> “Safety (clinical and laboratory evaluations) and efficacy are being assessed through 18 months”

Source: [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf)

<a id="topic-3.1.3.6.1-4"></a>

##### Developmental milestone gain or regain as the primary evidence of efficacy

> “As established COAs and CROs are not optimal measures of functional outcomes in small, open-label trials, measuring gain/regain of DMs presents an objective, data-driven way to assess the efficacy of TSHA-102 in a broad Rett syndrome population”

Source: [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf)

> “Primary evidence of efficacy (DM gain or regain): Applied rigorous evaluation criteria to available video-evidenced DM data that enabled a reliable, objective assessment of TSHA-102 efficacy (Figure 4)”
> “Baseline: Video data/medical history confirming milestone was either never gained or lost sufficiently long ago, such that the likelihood of spontaneous gain/regain is <6.7%”
> “Evaluation method: Determined by multiple independent central raters based on prespecified definitions of achievement for each milestone”
> “A recent analysis of Natural History Study (NHS) data demonstrated that patients reach a developmental plateau at ≥6 years of age”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.6.1-5"></a>

##### Supplemental efficacy scales: MSEL-A, ORCA, and R-MBA

> “Supportive evidence of functional gain: Supplemental analysis of skills and improvements derived from structured assessments (MSEL-A, R-MBA, and ORCA) demonstrated additional functional skill gains and improvements across core disease characteristics outside of the natural history defined DMs”
> “Adapted Mullen Scales of Early Learning (MSEL-A): Centrally rated video-recorded evaluation assessing expressive / receptive language skills”
> “Observer-Reported Communication Ability (ORCA): Caregiver-reported structured evaluation assessing communication skills”
> “Revised Motor Behavior Assessment (R-MBA): Clinician-reported video evaluation assessing frequency, severity or independence of Rett syndrome characteristics”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.6.1-6"></a>

##### RSBQ removed after FDA feedback

> “Based on FDA feedback from ongoing discussions, the Company intends to focus on objective measures that clinically capture functional gains; the Rett Syndrome Behavior Questionnaire (RSBQ) will not be included as a primary or secondary endpoint in Part B of the REVEAL trials”

Source: [Taysha Gene Therapies third quarter 2024 results announcement (2024)](https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/d877348dex991.htm)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned enrollment per trial

> “Part A of the study will focus on determining Maximum Administered Dose (MAD) and Maximum Tolerated Dose (MTD) in at least six patients (three per dose) aged 5-8 years old.”

Source: [Taysha Gene Therapies first pediatric participant dosed announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-pediatric-patient-dosed)

> “Dosing in cohort one (low dose, n=2) is now considered complete.”
> “Dosing of the first patient in cohort two (high dose, n=3) of 1x1015 total vg expected in the second quarter of 2024.”

Source: [Taysha Gene Therapies clinical program update announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-updates-tsha-102-clinical)

<a id="topic-3.1.3.7.1-2"></a>

##### Enrollment recorded in the registries

> “Enrollment of 6 participants in Part A is complete.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

| Field | Registry record |
| --- | --- |
| Enrollment (actual) | “6” |

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.7.1-3"></a>

##### Accrual over time

> “Dosed the third adolescent/adult patient in cohort two and enrolled the second pediatric patient in cohort two, with dosing scheduled for the current quarter”

Source: [Taysha Gene Therapies third quarter 2024 results announcement (2024)](https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/d877348dex991.htm)

> “The dataset includes six patients in cohort two (high dose, 1x1015 total vector genomes (vg)) and four patients in cohort one (low dose, 5.7x1014 total vg).”

Source: [Taysha Gene Therapies full-year 2024 results announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525035882/d920809dex991.htm)

<a id="topic-3.1.3.7.1-4"></a>

##### Participants analyzed at the May 2026 data cutoff

> “REVEAL Part A efficacy data based on the May 2026 data cutoff included 12 females with Rett syndrome aged 6-21 years (high dose, n=8; low dose, n=4) treated with the high dose (1x1015 total vg) or low dose (5.7x1014 total vg) of TSHA-102, each with ≥12 months of follow-up”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

> “n=8 patients with ORCA data, n=7 with MSEL-A data, and n=12 with R-MBA data.”
> “N=12 at 6 and 12 months, N=7 at ≥18 months post-TSHA-102.”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Analysis set and data cutoff for the 12-month results

> “Statistical analyses are based on May 2026 data cutoff (N=12).”
> “R-MBA assessed in Rett syndrome NHS at ~6 and ~12 months; MBA natural history data converted to R-MBA; mean scores reported were calculated from baseline to 6 and 12 months”
> “Developmental milestone gains and regains were assessed by multiple independent central raters through video evidence.”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.7.2-2"></a>

##### Natural history comparator sample sizes for R-MBA

| Time point | TSHA-102 | Natural history |
| --- | --- | --- |
| 6 months | “TSHA-102 (N=12) SD=10.18” | “Natural History (N=75) SD= 5.97” |
| 12 months | “TSHA-102 (N=12) SD=8.86” | “Natural History (N=196) SD= 5.73” |

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.7.2-3"></a>

##### Planned analysis relative to each participant's baseline (pediatric protocol design)

> “All Part A efficacy outcomes will be evaluated with descriptive statistics, relative to each participant’s baseline data.”

Source: [Devidze et al. (2023)](https://tayshagtx.com/wp-content/uploads/Design-of-the-REVEAL-Pediatric-study-of-TSHA-102-gene-therapy-for-Rett-Syndrome.pdf)

<a id="topic-3.1.3.7.2-4"></a>

##### Earlier analyses drawn from the electronic data capture system

> “Data presented reflects current data in the Electronic Data Capture System, subject to change.”

Source: [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### All 12 participants followed for at least 12 months

> “No treatment-related SAEs or DLTs observed in any patients, with all patients having ≥12 months of follow-up”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

> “The 12 patients treated in REVEAL Part A ranged from 6 to 21 years of age at dosing, with post-treatment follow-up spanning 12 to 30 months.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.3.8.1-2"></a>

##### Participants with data beyond 12 months

> “N=7 patients with data >12 months post-TSHA-102, N=5 patients with 12-month data.”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Age, severity, and genotype of the 12 participants

> “Patients were 6‒21 YOA, with diverse clinical histories, broad disease severity (CGI-S 4 to 6), and varied MECP2 mutations to reflect a real-world population”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

> “Baseline scores ranged from 4 to 6, reflecting moderately to severely ill patients.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.3.8.2-2"></a>

##### Individual participants: age at dosing, baseline CGI-S, and follow-up

| Cohort and participant | Age at dosing (years) | Baseline CGI-S score | Post-treatment follow-up (months) |
| --- | --- | --- | --- |
| Low dose, participant 1 | “20” | “6” | “30” |
| Low dose, participant 2 | “21” | “4” | “30” |
| Low dose, participant 3 | “6” | “5” | “24” |
| Low dose, participant 4 | “7” | “4” | “24” |
| High dose, participant 1 | “15” | “5” | “18” |
| High dose, participant 2 | “21” | “5” | “18” |
| High dose, participant 3 | “8” | “5” | “18” |
| High dose, participant 4 | “15” | “5” | “12” |
| High dose, participant 5 | “16” | “5” | “12” |
| High dose, participant 6 | “6” | “4” | “12” |
| High dose, participant 7 | “7” | “6” | “12” |
| High dose, participant 8 | “6” | “5” | “12” |

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.8.2-3"></a>

##### First two adult participants: stage four disease

> “20-year-old female at the time of dosing”
> “21-year-old female at the time of dosing”
> “Large MECP2 deletion affecting exons 3 and 4”
> “Missense MECP2 mutation (R133C)”
> “Complete loss of ambulation and wheelchair-bound by age 8”

Source: [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf)

<a id="topic-3.1.3.8.2-4"></a>

##### First two pediatric participants: stage three disease

> “6-year-old female at the time of dosing”
> “7-year-old female at the time of dosing”
> “Nonsense MECP2 mutation (R255X)”
> “Missense MECP2 mutation (R306C)”

Source: [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Responses at 6, 12, and at least 18 months (May 2026 data cutoff)

| Endpoint | 6 months (N=12) | 12 months (N=12) | 18 months or more (N=7) |
| --- | --- | --- | --- |
| Participants who gained or regained at least one developmental milestone | “83%” | “100%” | “100%” |
| Average functional gains per participant | “22” | “23” | “26” |
| R-MBA mean score change versus natural history | “-11.0 P = 0.0011” | “-10.3 P = 0.0002” | “-11.0 P = 0.0046” |
| Participants with CGI-I score of 3 or less at multiple post-treatment assessments | “100%” | “100%” | “100%” |
| Participants with CGI-S total score improvement | “25%” | “25%” | “57%” |

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.8.3-2"></a>

##### Developmental milestone response rate by time point

> “75% Response Rate (9/12)”
> “83% Response Rate (10/12)”
> “100% Response Rate (12/12)”
> “Response Rate = the % of patients who gain or regain ≥1 developmental milestone from a list of 28.”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.8.3-3"></a>

##### Number of developmental milestones and additional skills

> “At ≥12 months post-TSHA-102, a total of 310 functional gains and improvements were observed (~26 per patient), comprising 31 DMs and 279 additional skill gains/improvements”
> “DM gains increased by 69% from 6 to 12 months and by 94% from 6 to ≥12 months post TSHA-102”
> “16 DMs in pediatric (n=6) and 15 DMs in adolescent/adult (n=6) patients support the broad treatment potential of TSHA-102”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

> “According to the MSEL-A (53 skill gains), ORCA (128 skill gains) and R-MBA (98 improvements).”

Source: [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm)

<a id="topic-3.1.3.8.3-4"></a>

##### Milestones achieved across domains

> “100% of patients gained/regained ≥one developmental milestone across the core functional domains of fine motor, gross motor and communication post-TSHA-102 (i.e., spoke in phrases with meaning, used utensils to eat without assistance, walked with support), as assessed by multiple independent raters through video-evidenced evaluation”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="topic-3.1.3.8.3-5"></a>

##### R-MBA mean change from baseline versus natural history, by dose

| Time point | TSHA-102 mean change | Natural history mean change | P value |
| --- | --- | --- | --- |
| 6 months | “-11.0” | “-0.81” | “P = 0.0011” |
| 12 months | “-10.3” | “-0.62” | “P = 0.0002” |

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

> “-15.7 in high dose cohort”
> “-7.8 in low dose cohort”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.8.3-6"></a>

##### Dose comparison at the May 2025 data cutoff (10 participants)

| Endpoint | Low-dose cohort | High-dose cohort |
| --- | --- | --- |
| Developmental milestone responder rate at 6 months | “75%” | “83%” |
| R-MBA mean score improvement at 6 months | “-9.8” | “-12.2” |
| R-MBA mean score improvement at 9 months or more | “-11.5” | “-18.0” |
| Mean CGI-I score at 6 months | “2.3” | “2.0” |
| Mean CGI-I score at 9 months or more | “2.8” | “1.0” |
| Participants with CGI-S improvement at latest visit | “25%” | “33%” |

Source: [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf)

> “Previously aligned-upon key design elements remain unchanged, including a 6-month interim analysis that may serve as the basis for the BLA submission, which was enabled by the rigorous, objective evaluation criteria used to evaluate developmental milestone achievement in Part A of the REVEAL Phase 1/2 trials, and the 83% response rate seen at six months post-treatment following high dose TSHA-102 (5 out of 6 patients; May 2025 data cutoff) that deepened over time.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-3.1.3.8.3-7"></a>

##### Supplemental analysis at the May 2025 data cutoff

> “A total of 165 additional skills/improvements were achieved across the 10 patients, further supporting the potential broad and consistent therapeutic impact of TSHA-102 on functional abilities and activities of daily living”
> “The scales include the Adapted Mullen Scales of Early Learning (MSEL-A) evaluating defined communication skills (N=5 patients with available data), the Revised Motor Behavior Assessment (R-MBA) evaluating specific Rett syndrome disease characteristics (N=10 patients with available data), and the Observer-Reported Communication Ability (ORCA) evaluating communication skills (N=5 patients with available data).”

Source: [Taysha Gene Therapies 54th CNS Annual Meeting supplemental analysis announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525235212/d949053dex991.htm)

Additional sources: [Berry-Kravis et al. (2026b)](https://tayshagtx.com/wp-content/uploads/CNS-2026-REVEAL-12mo-data-encore-poster_approval.pdf); [Rossignol et al. (2025b)](https://tayshagtx.com/wp-content/uploads/Achieving-Developmental-Milestones-and-Broad-Restoration-of-Function-in-Rett-Syndrome-The-Potential-of-TSHA-102-Gene-Therapy.pdf); [Rossignol et al. (2024b)](https://tayshagtx.com/wp-content/uploads/TSHA-102-gene-therapy-for-Rett-syndrome-First-cohort-data-from-the-REVEAL-Adolescent-Adult-and-Pediatric-studies.pdf)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

##### Caregiver-reported communication (ORCA)

> “Observer-Reported Communication Ability (ORCA): Caregiver-reported structured evaluation assessing communication skills”
> “n=8 patients with ORCA data, n=7 with MSEL-A data, and n=12 with R-MBA data.”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

> “According to the MSEL-A (53 skill gains), ORCA (128 skill gains) and R-MBA (98 improvements).”

Source: [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm)

<a id="topic-3.1.3.8.4-2"></a>

##### Caregiver global impression (PGI-I) in the first adult participants

> “Global impressions show early (Week 4) improvement for both patients sustained through Week 52 for Patient 1 and Week 25 for Patient 2 as evaluated by clinicians and caregivers, respectively”

Source: [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf)

<a id="topic-3.1.3.8.4-3"></a>

##### Caregiver-reported behavior questionnaire (RSBQ)

> “The RSBQ is a 45-item questionnaire and is completed by the participant's Caregiver.”

Source: [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-3.1.3.8.4-4"></a>

##### Health-related quality of life instrument results

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Treatment-emergent adverse events across the 12 participants (May 2026 data cutoff)

| Event category | Low dose, participants | Low dose, events | High dose, participants | High dose, events | Total, participants | Total, events |
| --- | --- | --- | --- | --- | --- | --- |
| TEAE related to TSHA-102 | “4” | “17” | “5” | “20” | “9” | “37” |
| Serious TEAE unrelated to TSHA-102 | “3” | “9” | “4” | “8” | “7” | “17” |
| Serious TEAE related to TSHA-102 | “0” | “0” | “0” | “0” | “0” | “0” |

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.8.5-2"></a>

##### Most common treatment-related events, severity, and seizures

> “TSHA-102 was generally well tolerated at the low and high dose, with no treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLT) (Table 1)”
> “All TEAEs considered related to TSHA-102 were mild-moderate in severity, with the most common being elevated liver enzymes* (n=4, 33%), CSF protein increased (n=3, 25%) (clinically insignificant), pyrexia (n=3, 25%)”
> “Includes preferred terms: Gamma-glutamyltransferase increased, Hypertransaminasaemia, Liver function test increased, Transaminases increased.”
> “Seizures have generally been well controlled following TSHA-102”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.3.8.5-3"></a>

##### Transaminase pattern and other events at the May 2025 data cutoff

> “All TEAEs related to TSHA-102 were mild-moderate in severity, with the most common being elevated liver enzymes (N=4, 33%; includes hepatic enzyme increased, hypertransaminasemia, transaminases increased, and liver function test increased), pyrexia (N=3, 25%), lethargy (N=2, 17%), and elevated levels of NfL in CSF (clinically insignificant; N=2, 17%)”
> “Majority experience mild elevations <2x ULN”
> “Acute excursions (>5x ULN) less common, clinically asymptomatic and steroid treatment-responsive”

Source: [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf)

<a id="topic-3.1.3.8.5-4"></a>

##### Events in the first four low-dose participants, including immunosuppression-related events

> “TSHA-102 has been well tolerated with a total of 34 TEAEs as 05/10/2024. Of these, 33 were mild or moderate”
> “The most common AE overall was vomiting (5 TEAEs), a known risk of sirolimus”
> “Both patients had challenging side-effects related to immunosuppressant treatment.”
> “One serious adverse event, (severe, grade 3: change in seizure presentation) unrelated to TSHA-102, related to pre-existing disease and urine infection with multiple confounders (e.g., anesthesia, sleep deprivation)”
> “Eight nonserious events were related to immunosuppression (mild: vomiting (2), dermatitis acneiform, Cystatin C increase, blisters, myopathy) (moderate: chronic renal disease, myopathy)”

Source: [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf)

<a id="topic-3.1.3.8.5-5"></a>

##### Safety across Part A, the pivotal trial, and ASPIRE (November 2026 data cutoff)

> “TSHA-102 continue to be generally well tolerated with no severe treatment-related serious adverse events (SAEs) or dose limiting toxicities (DLTs) in all patients treated in the REVEAL Phase 1/2, REVEAL pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff.”
> “All patients in the REVEAL Phase 1/2 (n=12), pivotal (n=17) and ASPIRE (n=4) trials have cleared the acute post-dosing safety monitoring period typically associated with AAV gene therapies with no dose-limiting toxicities observed across all trials.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

Additional sources: [Rossignol et al. (2024a)](https://tayshagtx.com/wp-content/uploads/Early-safety-and-efficacy-observations-following-the-first-use-of-TSHA-102-gene-therapy-in-patients-with-Rett-Syndrome.pdf); [Taysha Gene Therapies low dose cohort data announcement (2024)](https://www.sec.gov/Archives/edgar/data/1806310/000119312524163050/d851091dex991.htm)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

- Pooled sample: REVEAL Part A combines two separately registered phase 1/2 dose-escalation trials, NCT05606614 Part A (females aged 12 to <22 years) and NCT06152237 (females aged 5 to 8 years), into one analysis of 12 participants, 4 at the low dose and 8 at the high dose. Comparisons between doses rest on groups of 4 and 8 participants, and comparisons between age groups on 6 pediatric and 6 adolescent or adult participants.
- No concurrent control: Part A of both trials is open label, and the 2026 poster describes each participant as their own control. Efficacy is judged against each participant's baseline and against external data from the Rett syndrome Natural History Study. The R-MBA comparison draws on natural history samples of 75 participants at 6 months and 196 at 12 months, with MBA scores converted to R-MBA.
- Efficacy endpoints outside the registered Part A outcomes: the registered primary outcome of Part A in both trials is the proportion or incidence of participants with treatment-emergent adverse events and serious adverse events. Developmental milestone gain or regain, the primary evidence of efficacy in the 2026 poster, is registered as the primary outcome of Part B, and the poster describes evaluation criteria applied to available video-evidenced milestone data. The counts of additional skills derived from the MSEL-A, ORCA, and R-MBA come from a supplemental analysis, with ORCA data for 8 and MSEL-A data for 7 of the 12 participants; an earlier company announcement reported 165 additional skills or improvements across 10 participants from the same scales.
- Masking: the pediatric trial is registered with no masking. In the adolescent and adult trial, only the central raters of milestone videos are masked, and only to the timing of each video. The R-MBA is a clinician-reported evaluation and ORCA a caregiver-reported evaluation, collected in open-label trials.
- Follow-up: all 12 participants had at least 12 months of follow-up (range 12 to 30 months), and results at 18 months or more rest on 7 participants.
- Concomitant immunosuppression: prednisolone and sirolimus begin 7 days before dosing and are tapered over the following months. In the company's 2024 first-cohort data presentation, the most common event, vomiting, was described as a known risk of sirolimus, and eight nonserious events were attributed to immunosuppression.
- Heterogeneous population: participants were 6 to 21 years of age at dosing, had baseline CGI-S scores of 4 to 6, and carried varied MECP2 mutations; the pediatric trial was opened to stage three Rett syndrome and the adolescent and adult trial to stage four Rett syndrome.
- Sponsor reporting: all results come from Taysha press releases, SEC filings, presentations, and congress posters, and the 2025 poster states that its data came from the electronic data capture system and were subject to change.
- Inconsistencies between documents: the low dose was stated as 5x10^14 vg in June 2023 and as 5.7x10^14 vg in the registry and the third quarter 2026 Form 10-Q. The third quarter 2026 Form 10-Q describes both trials as randomized and NCT06152237 lists randomized allocation, while NCT05606614 lists non-randomized allocation, the 2023 pediatric design poster describes Part A as a single-arm dose escalation, and the 2024 first-cohort presentation plans randomization in Part B. The 2024 announcements planned at least 3 participants per dose in the pediatric trial and 3 high-dose participants in the adolescent and adult trial; NCT05606614 enrolled 2 low-dose and 4 high-dose participants, and the 12 Part A participants comprised 4 low-dose and 8 high-dose participants.

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf); [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf); [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614); [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237); [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm); [Taysha Gene Therapies 54th CNS Annual Meeting supplemental analysis announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525235212/d949053dex991.htm); [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf); [Devidze et al. (2023)](https://tayshagtx.com/wp-content/uploads/Design-of-the-REVEAL-Pediatric-study-of-TSHA-102-gene-therapy-for-Rett-Syndrome.pdf); [Taysha Gene Therapies first participant dosed announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-patient-dosed-tsha-102); [Taysha Gene Therapies clinical program update announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-updates-tsha-102-clinical); [Taysha Gene Therapies first pediatric participant dosed announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-pediatric-patient-dosed); [Taysha Gene Therapies adolescent eligibility announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-expanded-eligibility-reveal)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
